| Title |
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer
|
|---|---|
| Published in |
Investigational New Drugs, March 2013
|
| DOI | 10.1007/s10637-013-9941-z |
| Pubmed ID | |
| Authors |
Isamu Okamoto, Keisuke Aoe, Terufumi Kato, Yukio Hosomi, Akira Yokoyama, Fumio Imamura, Katsuyuki Kiura, Tomonori Hirashima, Makoto Nishio, Naoyuki Nogami, Hiroaki Okamoto, Hideo Saka, Nobuyuki Yamamoto, Naoto Yoshizuka, Risa Sekiguchi, Kazuhiro Kiyosawa, Kazuhiko Nakagawa, Tomohide Tamura |
| Abstract |
This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-naïve patients with advanced nonsquamous non-small cell lung cancer (NSCLC). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sao Tome and Principe | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 19% |
| Researcher | 6 | 13% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Master | 4 | 9% |
| Lecturer | 3 | 6% |
| Other | 5 | 11% |
| Unknown | 15 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Social Sciences | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 16 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2014.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Investigational New Drugs
#846
of 1,262 outputs
Outputs of similar age
#134,698
of 208,639 outputs
Outputs of similar age from Investigational New Drugs
#12
of 13 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,262 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,639 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.